EQL Pharma today donates 2500 bottles of Hevicain (Bupivacain) to Ukraine via "Medical Procurement for Ukraine" https://medzakupivli.com/en/pro-mzu-eng/pro-nas-eng and wants to encourage other Swedish pharmaceutical companies to also donate medicines with special focus on the list of drugs with acute shortage that has been published, which includes bupivacaine. The list is published at: https://docs.google.com/spreadsheets/d/1Qe7mfaULMB2_iMZhTWZ3mCzmvAiDg_FE/

"Our drug Hevicain (bupivacaine), essential for many types of surgery, has now been picked up by courier and is on its way to Ukraine. Our donation does not affect the availability of bupivacaine for the Swedish market. Donating shortage medicines to Ukraine feels like the least we can do for the Ukrainian people ", says Christer Fåhraeus, CEO of EQL Pharma AB

Hevicain (bupivacaine) is a spinal anesthetic used in surgery on the abdomen, lower abdomen and legs.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 17 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2021 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 10 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.

https://news.cision.com/eql-pharma/r/eql-pharma-donates-2500-bottles-of-hevicain--bupivacaine--to-ukraine,c3518510

https://mb.cision.com/Main/11664/3518510/1544050.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English